---
title: "Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)"
description: "Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals. According to TipRanks, Meacham has an average return of 4.2% and a 55.14% success ra"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/260882169.md"
published_at: "2025-10-13T10:55:58.000Z"
---

# Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

> Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals. According to TipRanks, Meacham has an average return of 4.2% and a 55.14% success rate on recommended stocks. Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $488.86, which is a 19.88% upside from current levels. In a report released on October 9, Evercore ISI also maintained a Buy rating on the stock with a $475.00 price target.

Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Vertex Pharmaceuticals. According to TipRanks, Meacham has an average return of 4.2% and a 55.14% success rate on recommended stocks.

Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $488.86, which is a 19.88% upside from current levels. In a report released on October 9, Evercore ISI also maintained a Buy rating on the stock with a $475.00 price target.

### Related Stocks

- [VRTX.US - Vertex Pharma](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG) | Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG) | [Link](https://longbridge.com/en/news/275989081.md) |
| Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today | Vertex Pharmaceuticals (NASDAQ:VRTX) has delivered an average annual return of 17.22% over the past 15 years, outperform | [Link](https://longbridge.com/en/news/276269422.md) |
| Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum | In a recent report, Craig-Hallum analyst Albert Lowe maintained a Buy rating on Palvella Therapeutics (PVLA) with a pric | [Link](https://longbridge.com/en/news/276240277.md) |
| Vertex Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day | Vertex Pharmaceuticals Inc. (VRTX) shares fell 1.47% to $470.31, marking the second consecutive day of losses, despite a | [Link](https://longbridge.com/en/news/276275589.md) |
| BofA Maintains Stc at Buy Amid Expected Operational Catalysts | BofA Maintains Stc at Buy Amid Expected Operational Catalysts | [Link](https://longbridge.com/en/news/276232847.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.